Transfusion-related acute lung injury (TRALI) continues to be the leading cause of transfusion-related death, and therefore, an important issue for the blood bank and transfusion medicine communities. Three lectures will be presented reviewing recent research findings made concerning HNA-3a antibodies, class I and II HLA antibodies, and bioactive lipids in TRALI. The first speaker will review findings that choline transporter-like protein 2 (CTL2) is the protein carrier of HNA-3a/3b, the HNA-3a/3b genetic polymorphism, and recent work to develop a blood donor screening assay for HNA-3 antibodies. The second speaker will describe data on the frequency of HLA class II antibodies in TRALI and recent studies on the mechanism for HLA class II antibodies in TRALI. The third speaker will describe findings made with recent rat model studies and how this data has advanced our understanding of the mechanisms responsible for TRALI caused by HLA class I antibodies and bioactive lipids.